Меню
Набор скоро начнётся NCT07640061

Pilot Studies Testing the Use of Oral Amitriptyline in Reducing Localized Burn Injury-induced Microvesicle Particle Release

Фаза I С лечением Microvesicle Particles Thermal Burn

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Amitriptyline, Placebo.
Кому может быть актуально
Состояния в реестре: Microvesicle Particles, Thermal Burn. Базовые параметры: 18 лет — 60 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
США
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Обзор

The purpose of this study is to determine the amount of substances contained in skin known as microvesicle particles (MVP). The hypothesis to be tested in this study is that treatment with a single dose of 75mg of amitriptyline will block the MVP released from the skin from a very small localized burn injury.

Подробное описание

The purpose of this study is to determine the amount of substances contained in skin known as microvesicle particles (MVP). Studies suggest these MVP are involved in many conditions such as after the thermal burn injury. In fact, there is evidence suggesting that these MVP cause severe toxic effects and could be responsible for deaths following extensive thermal burn injuries. These particles are typically found in skin and are evaluated by taking a portion of area with skin biopsy. Of importance, MVP release from the skin can be blocked by drugs such as amitriptyline, a medicine which is a tricyclic anti-depressant. The hypothesis to be tested in this study is that treatment with a single dose of 75mg of amitriptyline will block the MVP released from the skin from a very small localized burn injury. This study is evaluating the amount of MVP made in the skin following a localized injury with heat and then conducting small skin biopsies. Additionally, samples from the inside of the nostrils are collected. By utilizing these methods after taking oral amitriptyline and then comparing them after taking a placebo, the investigator can see if taking the amitriptyline causes lesser amounts of MVP in the skin and nose cells.

Вмешательства

  • Препарат Amitriptyline
    75mg amitriptyline
  • Препарат Placebo
    Placebo

Первичные конечные точки

  • Change from Baseline in MVP Release in Skin from a localized thermal burn injury in response to oral amitriptyline versus placebo as measured by skin biopsy [Срок оценки: 2 hours after the burn injury]
Вторичные конечные точки (1)
  • Change in MVP release of nasal mucosal cells obtained from one nostril before and other nostril 90 min after subject ingests placebo or 75mg amitriptyline [Срок оценки: 2 hours after burn injury]

Критерии участия

Критерии включения

  • Adult Males and Females age 18 - 60
  • All skin types on Fitzpatrick Scale (Type I-VI)
  • Able to comprehend procedures and risks
  • Willing to participate and understand the informed consent document
  • Have reliable transportation

Критерии исключения

  • Subjects should be otherwise healthy and not have any significant medical issues that could interfere with the study, in particular any heart arrythmias and not be on any prescription medications that could react with amitriptyline.
  • History of abnormal scarring (i.e., keloids) or poor wound healing.
  • No over the counter non-steroidal anti-inflammatory agents (aspirin, acetaminophen) or antioxidant vitamins (vitamin C) in past 14 days.
  • Currently taking known photosensitizers, anti-inflammatories, other tricyclic antidepressants, or systemic agents known to be aSMase inhibitors
  • Large tattoos in designated testing areas
  • Tanning bed use within last 3 months
  • UVB treatments in past 3 months
  • Medical history of abnormal scarring or diseases that could affect wound healing
  • Medical history of hypertension/hypotension or heart problems
  • Pregnant or nursing
  • History of sores in nares or easy bleeding from nares or other bleeding disorders.
  • Nasal piercings
  • Known allergies to lidocaine or amitriptyline

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Да

Дизайн исследования

Распределение
Рандомизированное
Модель
Перекрёстный дизайн
Маскирование
Двойное слепое
Основная цель
Профилактика

Центры проведения

США · 1 центр
  • Wright State University - Pharmacology Translational Unit — Fairborn

Идентификаторы

NCT: NCT07640061 · IRB-2026-1023

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗